173 related articles for article (PubMed ID: 20873523)
1. European Court of Justice. ECJ 2010/6 Association of the British Pharmaceutical Industry v. Medicines and Healthcare Products Regulatory Agency, 22 April 2010 (C-62/09).
Baeyens A; Goffin T
Eur J Health Law; 2010 Sep; 17(4):415-9. PubMed ID: 20873523
[No Abstract] [Full Text] [Related]
2. Life after SGR: What's Next for Physician Practices?
Silversmith J
Minn Med; 2015; 98(11-12):35-7. PubMed ID: 26720940
[No Abstract] [Full Text] [Related]
3. An insider's perspective: defense of the pharmaceutical industry's marketing practices.
Johar K
Albany Law Rev; 2012-2013; 76(1):299-334. PubMed ID: 23577377
[No Abstract] [Full Text] [Related]
4. No cancer patient has to live in pain, but many still do.
McNeil C
J Natl Cancer Inst; 1997 Sep; 89(17):1250-2. PubMed ID: 9293910
[No Abstract] [Full Text] [Related]
5. Moves to eliminate 'anticompetitive' practices in the supply of prescription-only veterinary medicines.
Vet Rec; 2003 Apr; 152(16):482-4. PubMed ID: 12733556
[No Abstract] [Full Text] [Related]
6. India's generics-only drug policy could put health at risk.
Gourd E
Lancet Oncol; 2017 Jul; 18(7):e373. PubMed ID: 28583793
[No Abstract] [Full Text] [Related]
7. 'Showdown in Cow Town': Texas MDs balk at contract.
Physician Relat Update; 1998 Nov; 7(11):125-6. PubMed ID: 10345020
[No Abstract] [Full Text] [Related]
8. Industry relationships with physicians under scrutiny.
Beller GA
J Nucl Cardiol; 2008; 15(6):737-8. PubMed ID: 18984446
[No Abstract] [Full Text] [Related]
9. Can CAM come in from the cold? An update on the ongoing regulatory process with regard to herbal and acupuncture practitioners in the United Kingdom.
McIntyre M
J Altern Complement Med; 2003 Dec; 9(6):809-10. PubMed ID: 14736350
[No Abstract] [Full Text] [Related]
10. Survey provides insight into prescribing under the cascade.
Vet Rec; 2014 May; 174(20):489. PubMed ID: 24832875
[No Abstract] [Full Text] [Related]
11. Sorrell v. IMS Health Inc.: data mining of pharmacy records and drug marketing as free speech.
Cartwright-Smith L; Lopez N
Public Health Rep; 2013; 128(1):64-6. PubMed ID: 23277662
[No Abstract] [Full Text] [Related]
12. [Prescribing fictitiously approved drugs: regress threatens!].
Walbert H
MMW Fortschr Med; 2012 Apr; 154(6):10. PubMed ID: 22642016
[No Abstract] [Full Text] [Related]
13. BC Supreme Court begins hearing doctors' class-action lawsuit.
Williams J
CMAJ; 2013 Aug; 185(11):E521. PubMed ID: 23754109
[No Abstract] [Full Text] [Related]
14. Physicians' liability for off-label prescriptions.
Riley JB; Basilius PA
Nephrol News Issues; 2007 Jun; 21(7):43-4, 46-7. PubMed ID: 17623984
[No Abstract] [Full Text] [Related]
15. Take this medicine: the legality of prescription incentive schemes.
Fanning J; Glover-Thomas N
Med Law Rev; 2010; 18(3):417-26. PubMed ID: 20739438
[No Abstract] [Full Text] [Related]
16. Off-label marketing stirs a legal hornet's nest.
Guglielmo WJ
Med Econ; 2006 Oct; 83(19):47-9. PubMed ID: 17066854
[No Abstract] [Full Text] [Related]
17. Stopping the practice of authorized generics: Mylan's effort to close the gaping black hole in the Hatch-Waxman act.
Porter B
J Contemp Health Law Policy; 2005; 22(1):177-209. PubMed ID: 16680993
[No Abstract] [Full Text] [Related]
18. Gynaecologist whose erasure was quashed in High Court is fit to practise.
Dyer C
BMJ; 2018 Nov; 363():k4760. PubMed ID: 30409897
[No Abstract] [Full Text] [Related]
19. Undermining the hippocratic oath: the Medical Innovation Bill.
Lancet Oncology
Lancet Oncol; 2015 Jan; 16(1):1. PubMed ID: 25434749
[No Abstract] [Full Text] [Related]
20. The pharmaceutical industry: friend or foe?
Niebyl JR
Am J Obstet Gynecol; 2008 Apr; 198(4):435-9. PubMed ID: 18395035
[No Abstract] [Full Text] [Related]
[Next] [New Search]
